Michelle Miller

Michelle Miller

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Science
Verified
Journal Article
Closed access
EHEmily Han-Chung Hsiue
Emily Han-Chung Hsiue
KWKatharine M. Wright
Katharine M. Wright
JDJacqueline Douglass
Jacqueline Douglass
MHMichael S. Hwang
Michael S. Hwang
BMBrian J. Mog
Brian J. Mog
SZShibin Zhou
Shibin Zhou
Turning a tumor suppressor into a target: Tumor-suppressor genes such as TP53 (tumor protein P53) play key roles in the pathogenesis of cancer but, unfortunately, they are difficult to target because they do not create an overactive protein that can be inhibited with a drug. Hsiue et al. discovered a way to target a cancer-associated mutant form of the p53 protein using the body's own immune system (see the Perspective by Weidanz). The authors identified a distinct fragment of this mutant protein, characterized the structural basis for its presentation to T cells, and designed a bispecific antibody to stimulate T cell killing of p53-mutant cancer cells. Science , this issue p. eabc8697 ; see also p. 996

4 March 2021 in Science Immunology
Verified
Journal Article
Closed access
JDJacqueline Douglass
Jacqueline Douglass
EHEmily Han-Chung Hsiue
Emily Han-Chung Hsiue
BMBrian J. Mog
Brian J. Mog
MHMichael S. Hwang
Michael S. Hwang
SDSarah R. DiNapoli
Sarah R. DiNapoli
SZShibin Zhou
Shibin Zhou
Bispecific T cell–engaging antibodies capable of specifically killing cancer cells expressing mutant RAS neoantigens were generated.

1 January 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SCSamit Chatterjee
Samit Chatterjee
WLWojciech G. Lesniak
Wojciech G. Lesniak
MMMichelle Miller
Michelle Miller
ALAla Lisok
Ala Lisok
ESEmilia Sikorska
Emilia Sikorska
SNSridhar Nimmagadda
Sridhar Nimmagadda

26 February 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
MMMichelle Miller
Michelle Miller
PTPhilip Thompson
Philip Thompson
SGSandra B. Gabelli
Sandra B. Gabelli
Phosphatidylinositol 3-kinases (PI3Ks) are important therapeutic targets for the treatment of cancer, thrombosis, and inflammatory and immune diseases. The four highly homologous Class I isoforms, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ have unique, non-redundant physiological roles and as such, isoform selectivity has been a key consideration driving inhibitor design and development. In this review, we discuss the structural biology of PI3Ks and how our growing knowledge of structure has influenced the medicinal chemistry of PI3K inhibitors. We present an analysis of the available structure-selectivity-activity relationship data to highlight key insights into how the various regions of the PI3K binding site influence isoform selectivity. The picture that emerges is one that is far from simple and emphasizes the complex nature of protein-inhibitor binding, involving protein flexibility, energetics, water networks and interactions with non-conserved residues.

25 July 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
MMMichelle Miller
Michelle Miller
OSOleg Schmidt-Kittler
Oleg Schmidt-Kittler
DBDavid M. Bolduc
David M. Bolduc
EBEvan T. Brower
Evan T. Brower
DCDaniele Chaves-Moreira
Daniele Chaves-Moreira
SGSandra B. Gabelli
Sandra B. Gabelli
We report two crystal structures of the wild-type phosphatidylinositol 3-kinase α (PI3Kα) heterodimer refined to 2.9 Å and 3.4 Å resolution: the first as the free enzyme, the second in complex with the lipid substrate, diC4-PIP2, respectively. The first structure shows key interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that suggest a mechanism by which the enzyme is inhibited in its basal state. In the second structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding site, bordered by the P-loop, the activation loop and the iSH2 domain. An additional lipid-binding site was identified at the interface of the ABD, iSH2 and kinase domains. The ability of PI3Kα to bind an additional PIP2 molecule was confirmed in vitro by fluorescence quenching experiments. The crystal structures reveal key differences in the way the nSH2 domain interacts with wild-type p110α and with the oncogenic mutant p110αH1047R. Increased buried surface area and two unique salt-bridges observed only in the wild-type structure suggest tighter inhibition in the wild-type PI3Kα than in the oncogenic mutant. These differences may be partially responsible for the increased basal lipid kinase activity and increased membrane binding of the oncogenic mutant.

1 August 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SMSweta Maheshwari
Sweta Maheshwari
MMMichelle Miller
Michelle Miller
RORobert O'MEally
Robert O'MEally
RCRobert N. Cole
Robert N. Cole
LAL. Mario Amzel
L. Mario Amzel
SGSandra B. Gabelli
Sandra B. Gabelli
Phosphoinositide 3-kinases (PI3Ks) are ubiquitous lipid kinases that activate signaling cascades controlling cell survival, proliferation, protein synthesis, and vesicle trafficking. PI3Ks have dual kinase specificity: a lipid kinase activity that phosphorylates the 3′-hydroxyl of phosphoinositides and a protein-kinase activity that includes autophosphorylation. Despite the wealth of biochemical and structural information on PI3Kα, little is known about the identity and roles of individual active-site residues in catalysis. To close this gap, we explored the roles of residues of the catalytic domain and the regulatory subunit of human PI3Kα in lipid and protein phosphorylation. Using site-directed mutagenesis, kinetic assays, and quantitative mass spectrometry, we precisely mapped key residues involved in substrate recognition and catalysis by PI3Kα. Our results revealed that Lys-776, located in the P-loop of PI3Kα, is essential for the recognition of lipid and ATP substrates and also plays an important role in PI3Kα autophosphorylation. Replacement of the residues His-936 and His-917 in the activation and catalytic loops, respectively, with alanine dramatically changed PI3Kα kinetics. Although H936A inactivated the lipid kinase activity without affecting autophosphorylation, H917A abolished both the lipid and protein kinase activities of PI3Kα. On the basis of these kinetic and structural analyses, we propose possible mechanistic roles of these critical residues in PI3Kα catalysis.